Skip to the page

Data / Federal grants / PAR-25-374

Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

National Institutes of Health (Department of Health and Human Services) is accepting applications until May 7, 2028. It lists awards of up to $1 million, $1 million in total.

SpecStream is the live web data engine for teams and agents. It reads every open and forecast federal opportunity on Grants.gov each morning, and this page is that reading. Describe your organization once and the grants that fit arrive in your sheet, CRM, Slack or agent as they are posted.

Key facts

Opportunity number
PAR-25-374
Status
Posted, open
Posted
December 30, 2024
Closes
May 7, 2028
Award ceiling
$1,000,000
Total funding
$1,000,000
Cost sharing
Not required
Funding instrument
Grant
Category
Health
Assistance listing
93.866 Aging Research; None None
Contact
National Institutes of Health · [email protected] · 301-402-2541

Who can apply

  • Public and State controlled institutions of higher education
  • For profit organizations other than small businesses
  • City or township governments
  • Independent school districts
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Private institutions of higher education
  • Public housing authorities/Indian housing authorities
  • Small businesses
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • County governments
  • State governments
  • Special district governments
  • Native American tribal governments (Federally recognized)
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

What the agency says

This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.

The notice on Grants.gov Full announcement

Other open grants from the Department of Health and Human Services

All grants open to Public colleges and universities · All grants open to For profit organizations other than small businesses · All grants open to City or township governments · Everything closing in May 2028

Read from the Grants.gov API, last updated 2026-10-23. The agency's notice on Grants.gov is the official record; check it before you apply.